oxyphenonium

Trade name: antrenyl

Small moleculeapproved

Oxyphenonium bromide is a quaternary ammonium anticholinergic agent, which was used under brand name antrenyl, to relieve visceral spasms and as an adjunct in the treatment of peptic ulcer. In addition, Oxyphenonium inhibits gastrointestinal propulsive motility and decreases gastric acid secretion and controls excessive pharyngeal, tracheal and bronchial secretions. Action is achieved via a dual mechanism: a specific anticholinergic effect (antimuscarinic) at the acetylcholine-receptor sites and a direct effect upon smooth muscle. Oxyphenonium bromide also been used in the form of eye drops for mydriatic effec — NCATS

Clinical trial activity

0 trials · 0 clinical orgs · 2 marketing orgs

Phase 1
0
Phase 2
0
Phase 3
0
Phase 4
0

Timeline

1950s

  1. Jun 1, 1952

    Ciba — First NDA Organization

  2. Jun 1, 1952

    Ciba — NDA Organization

Indications

Mechanism of action

Approval history

  • approved

Chemistry & pharmacology

Loading structure…

SMILES

CC[N+](C)(CC)CCOC(=O)C(O)(c1ccccc1)C1CCCCC1
Mol. weight
348.51 g/mol
Lipinski Ro5
Pass
Rule of 3
No
Chirality
Racemic Mixture
Inorganic
No
Polymer
No
Delivery
Oral
Availability
Discontinued

Oral

Yes

Parenteral

No

Topical

No

Sources

Also known as

  • antrenyl
  • antrenyl
  • antrenyl
  • antrenyl
  • antrenyl
  • antrenyl
  • antrenyl
  • oxyphenonium
  • oxyphenonium
  • oxyphenonium
  • oxyphenonium
  • oxyphenonium
  • oxyphenonium
  • oxyphenonium
  • oxyphenonium bromide
  • oxyphenonium bromide
  • oxyphenonium bromide
  • oxyphenonium bromide
  • oxyphenonium cation
  • oxyphenonium cation
  • oxyphenonium ion
  • oxyphenonium ion

Organizations

Marketing (2)

OrganizationOrg typeRelationshipDate
CibaFor profitNDAJun 1, 1952
NovartisFor profitNDA2